Global Lung Cancer Diagnostics Market - 2025-2033

The global lung cancer diagnostics market reached US$ 4.94 billion in 2024 and is expected to reach US$ 8.44 billion by 2033, growing at a CAGR of 6.18% during the forecast period 2025-2033.

Lung cancer diagnostics are crucial for early detection, accurate diagnosis, and effective treatment of lung cancer, which remains one of the leading causes of cancer-related deaths worldwide. Detecting lung cancer early is vital for determining the best course of treatment and improving survival rates. A variety of diagnostic methods are used, including imaging techniques like CT scans, X-rays, and PET scans, as well as biomarker testing and genetic analysis.

Liquid biopsy, a newer and non-invasive technology, is also gaining popularity for identifying genetic mutations and specific characteristics of the cancer. These advancements have made it possible to create more personalized treatment plans, such as targeted therapies or immunotherapies, which are showing promising results in improving patient outcomes.

Market Dynamics: Drivers & Restraints

Rising incidence of lung cancer cases

The rising incidence of lung cancer is a key factor driving the growth of the lung cancer diagnostics market. As the number of cases continues to increase worldwide, there's a greater need for effective and early detection methods. Lung cancer remains one of the deadliest and most common cancers, largely due to factors like smoking, air pollution, and other environmental influences.

With more people being diagnosed each year, the demand for advanced diagnostic tools to catch the disease at an earlier, more treatable stage has grown significantly. For instance, according to the American Cancer Society, it is estimated that about 226,650 new cases of lung cancer cases are expected to report in 2025. Lung cancer statistics typically encompass both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Generally, SCLC accounts for about 13% of all lung cancer cases, while NSCLC makes up approximately 87%.

As the number of lung cancer cases rises, both healthcare providers and patients are looking for more accurate, efficient, and accessible diagnostic options to improve survival rates. Early detection is essential for better outcomes, and there's an increasing need for screening tools like low-dose CT scans and biomarker testing. Thus, the growing number of lung cancer cases is a major driver for the lung cancer diagnostics market.

High Costs of Diagnostic Tests

The high cost of diagnostic tests poses a significant challenge to the growth of the lung cancer diagnostics market by restricting access to advanced technologies, especially in low- and middle-income regions. Expensive diagnostic methods, such as liquid biopsies, genomic testing, and PET scans, are often financially inaccessible to many patients, resulting in delayed diagnoses or reliance on less precise, more affordable alternatives.

Segment Analysis

The global lung cancer diagnostics market is segmented based on cancer type, diagnostic test type, product type, end-user, and region.

Treatment:

Biopsy segment is expected to dominate the global lung cancer diagnostics market share

The biopsy segment is expected to lead the lung cancer diagnostics market because it plays a vital role in accurately diagnosing lung cancer. Methods like needle biopsies, bronchoscopic biopsies, and surgical biopsies are essential for confirming the presence of cancer cells and determining the type and stage of the disease. Different biopsy tests are introduced by the companies to enhance the accuracy of the diagnostic procedures. For instance, in October 2023, Delfi Diagnostics introduced its first liquid biopsy test, fulfilling the company's long-standing goal of providing a blood-based screening tool for lung cancer. The Firstlook Lung test aims to offer a more accessible and convenient detection method, reaching a broader population compared to current standards.

Recent advancements in minimally invasive techniques, such as CT-guided needle biopsies and EBUS-guided biopsies, have made it easier to collect tissue samples with fewer risks, which has led to wider adoption in clinical practice. Companies are forming partnerships to widen the usage pof the existing tests and products. For instance, in January 2023, Agilent and Quest Diagnostics have partnered to broaden access to the Agilent Resolution ctDx FIRST liquid biopsy next-generation sequencing (NGS) test. This FDA-approved, single-site premarket test serves as a companion diagnostic (CDx) to identify patients with advanced non-small cell lung cancer (NSCLC) who may benefit from treatment with adagrasib (brand name Krazati).

As precision medicine continues to gain importance, biopsies are key for genomic profiling and identifying biomarkers, which are crucial for selecting the most effective targeted therapies and immunotherapies. This ability to support personalized treatment is a major factor driving the dominance of the biopsy segment in the market.

Geographical Analysis

North America is expected to hold a significant position in the global lung cancer diagnostics market share

North America is expected to maintain a dominant position in the global lung cancer diagnostics market, driven by its advanced healthcare infrastructure and high lung cancer incidence. The region's access to cutting-edge diagnostic technologies, such as advanced imaging systems, liquid biopsies, and genomic testing, enables early and accurate detection of lung cancer, which is crucial for improving patient outcomes.

Growing awareness about the importance of early lung cancer screening, along with a rising emphasis on precision medicine, has fuelled the demand for effective and personalized diagnostic solutions. Moreover, the significant investments in healthcare research for diagnostic procedures, ensure that patients have greater access to the latest diagnostic tools. For instance, in October 2023, DELFI Diagnostics, Inc., a company focused on accessible blood-based tests to improve cancer detection, has announced the initial commercial launch of FirstLook Lung. This blood test provides a convenient, accurate, and personalized result by assessing the likelihood of detecting lung cancer through low-dose CT (LDCT), boasting an impressive negative predictive value (NPV) of 99.7%. These factors hold the region in the dominant position in the lung cancer diagnostics market.

Competitive Landscape

The major global players in the lung cancer diagnostics market include Quest Diagnostics Incorporated, Biodesix, Lepu Medical Technology (Beijing)Co., Ltd., DSS Imagetec, Abbott, Guardant Health, Intuitive Surgical, bioAffinity Technologies, Inc., Optellum Ltd and F. Hoffmann-La Roche Ltd. among others.

Key Developments

• In January 2025, Monitor Corporation has begun selling its lung cancer diagnosis software in Japan through a partnership with Doctor-NET, a Japanese digital healthcare provider.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Lung Cancer Diagnostics Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.